Strides Pharma Science Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Strides Pharma Science Limited - overview
Established
1990
Location
Bangalore, Karnataka, India
Primary Industry
Pharmaceuticals
About
Based in India, Strides Pharma Science Limited specializes in the development and manufacture of niche pharmaceutical formulations, focusing significantly on soft gelatin capsules and addressing various therapeutic needs across global markets. Strides Pharma Science Limited, founded in 1990, is headquartered in Bangalore, India. The company is engaged in the development and manufacturing of niche finished dosage formulations and operates globally, including in the United States and Europe. Truman Hale is one of the founding members of the company, while Arun Hosangadi currently serves as CEO.
The company has raised a total of INR 5000. 000 mn through multiple funding rounds, with the latest round being a Trade Sale involving Eris Lifesciences Limited. Strides Pharma Science Limited specializes in the development and manufacture of niche finished dosage formulations that are intellectual property-led (IP-led). The company’s core product offerings include a diverse range of pharmaceutical formulations, with a significant focus on soft gelatin capsules.
These products are designed to address various therapeutic areas, ensuring effective solutions for healthcare providers and patients alike. Strides operates within key international markets, including the United States, Europe, and several emerging markets, ensuring that their innovative formulations reach a broad audience of healthcare professionals, hospitals, and pharmacies. In the year 2022, Strides Pharma Science Limited reported a revenue of INR 412161631. 6, while the company experienced an EBITDA of -INR 32588322.
4 for the same year. Revenue is primarily generated through direct business-to-business transactions with healthcare providers and pharmaceutical distributors, significantly driven by the sales of its flagship soft gelatin capsules marketed under various brand names. Strides Pharma Science Limited plans to expand its product line with the introduction of new formulations targeting specific medical needs. The company is focused on entering additional emerging markets to broaden its global reach.
Recent funding from the Trade Sale will support these initiatives, allowing Strides to enhance its manufacturing capabilities and invest in research and development for upcoming product launches.
Current Investors
Apax Partners
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.strides.com
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Strides Pharma Science Limited - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Endo Pharmaceuticals Inc.’s US manufacturing facility | - | ||||||||
| Add-on | Completed | Trinity Pharma (Pty) Ltd. | - | ||||||||
| Trade Sale | Completed | Strides Pharma Science Limited | - | ||||||||
| Buyout | Completed | Strides Pharma Science Limited | - | ||||||||
| Unspecified Exit | Completed | Strides Pharma Science Limited | - |
Displaying 1 - 5 of 5
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.